Guest Blogger

Articles

The Pharma Leadership Challenge: Thawing the “Frozen” Middle Managers

The challenge for senior leadership is to enable the layers of middle management to work to their full potential. Mike Straw argues that ‘failing fast’ should become the new mantra if pharma is going to drive greater innovation and creativity.

Showing Patients the Bigger Mobile Health Picture

To understand just how far mobile and digital technology can truly influence progress in global healthcare, we first need to form the foundation of the discussion with a few rudimentary facts.

Preparing for Reentry: A Physician’s Story

You would expect that, given a physician shortage, my goal of getting back into obstetrics would be supported and even welcomed.

NIH Invests in Biomedical Big Data

The National Institutes of Health (NIH) announced yesterday that it is issuing nearly $32 million in grants for the development of strategies to analyze and leverage biomedical data sets.

Sequestration: What Does it Mean for Pharma?

Lurking in the shadows of the US General Elections is something called The Sequestration Transparency Act of 2011.

Is the Worst of the Patent Cliff Behind Us?

In a bit of good news for pharma, Moody’s Investors Service has upgraded its outlook for the global pharmaceutical industry to stable.

ePatient Connections: Highlights from This Year’s Summit

This month’s ePatient Connections Summit in Philadelphia, PA, saw biopharmaceutical firms, medical device companies, and patient advocates discuss best practices for engaging patients online and in social media settings.

What's the Future of European Health Policy?

What can be gleaned about the direction that health policy will take for the next five years under the new European Commission, scheduled to take office at the beginning of November? Peter O’ Donnell address this question in his new Applied Clinical Trials column here.

Doctors, Data, and Drug Development

It is estimated that applying big data strategies could potentially generate up to $100 billion in value annually across the US healthcare systems, specifically by optimizing innovation and improving the efficiency of research and clinical trials.

Pharma M&A: Diverse and Accelerating

Although it is true that there are many legitimate ways to succeed, a host of these strategies appear to be diametrically opposite of one another: Diversified versus pure play, generic versus ethical, regional versus global, R&D versus limited R&D, organic development versus acquisitions, and so on.